• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Janux Therapeutics Inc. (Amendment)

    2/14/24 5:53:09 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JANX alert in real time by email
    SC 13G/A 1 janx13ga.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. 1)

    Janux Therapeutics, Inc.

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    47103J105

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X]       Rule 13d-1(b)

    [X]       Rule 13d-1(c)

    [ ]       Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     1 
    CUSIP No. 47103J105

     

     

    1.Names of Reporting Persons.

    EcoR1 Capital, LLC

     

    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) X

    (b)

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-
    6. Shared Voting Power -0-
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power -0-

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person -0-

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 0%

     

    12.Type of Reporting Person (See Instructions) OO, IA

     2 
    CUSIP No. 47103J105

     

     

    1.Names of Reporting Persons.

    Oleg Nodelman

     

    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) X

    (b)

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization United States

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-
    6. Shared Voting Power -0-
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power -0-

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person -0-

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 0%

     

    12.Type of Reporting Person (See Instructions) IN, HC

     

     3 
    CUSIP No. 47103J105

     

     

     

    1.Names of Reporting Persons.

    EcoR1 Capital Fund Qualified, L.P.

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) ______

     

    3. SEC Use Only

     

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power -0-

     

    6. Shared Voting Power -0-
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power -0-

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person -0-

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 0%

     

    12.Type of Reporting Person (See Instructions) PN

     

     

     4 
    CUSIP No. 47103J105

     

    Item1.
    (a)Name of Issuer

    Janux Therapeutics, Inc.

     

    (b)Address of Issuer’s Principal Executive Offices

    10955 Vista Sorrento Parkway, Suite 200, San Diego, CA 92130

    ________________________________________________________________________

    Item2.
    (a)The names of the persons filing this statement are:

    EcoR1 Capital Fund Qualified, L.P. (“Qualified Fund”), EcoR1 Capital, LLC (“EcoR1”) and Oleg Nodelman (“Nodelman”) (collectively, the “Filers”).

     

    Qualified Fund is filing this statement jointly with the other Filers, but not as a member of a group and it expressly disclaims membership in a group. In addition, filing this Schedule 13G on behalf of Qualified Fund should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any of the Stock covered by this Schedule 13G.

     

    Each Filer also disclaims beneficial ownership of the Stock except to the extent of that person’s pecuniary interest therein.

     

    (b)The principal business office of the Filers is located at:

    357 Tehama Street #3, San Francisco, CA 94103

     

    (c)For citizenship of Filers, see Item 4 of the cover sheet for each Filer.

     

    (d)This statement relates to the Issuer’s shares of Common Stock, par value $0.001 per share (the “Stock”).

     

    (e)The CUSIP number of the Issuer is: 47103J105.
     5 
    CUSIP No. 47103J105

     

    Item 3.If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)[ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b)[ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)[ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d)[ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e)[ X ] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E) as to EcoR1.
    (f)[ ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).
    (g)[ X ] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G)
    as to Mr. Nodelman.
    (h)[ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
    (i)[ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
    (j)[ ] Group, in accordance with section 240.13d-1(b)(1)(ii)(J).
    Item 4.Ownership.

    See Items 5-9 and 11 of the cover page for each Filer.

    Item 5.Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ X ].

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

    EcoR1 is the general partner and investment adviser of investment funds, including Qualified Fund. Mr. Nodelman is the control person of EcoR1.

     

    Item 9.Notice of Dissolution of Group.

    Not applicable.

    Item 10.Certification.

    Certification of EcoR1 and Mr. Nodelman:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    Certification of Qualified Fund:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 14, 2024

     

    EcoR1 CAPITAL, LLC

     

     

    By:/s/ Oleg Nodelman

    Oleg Nodelman, Manager

     

     

     

     

     

    /s/ Oleg Nodelman
    Oleg Nodelman

    EcoR1 CAPITAL FUND QUALIFIED, L.P.

     

    By: EcoR1 Capital, LLC, General Partner

     

     

    By: /s/ Oleg Nodelman

    Oleg Nodelman, Manager

     

     
     6 
    CUSIP No. 47103J105

    EXHIBIT A

    AGREEMENT REGARDING JOINT FILING
    OF STATEMENT ON SCHEDULE 13D OR 13G

    The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D, Schedule 13G or Forms 3, 4 or 5 (and any amendments or supplements thereto) required under section 13(d) or 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned hereby constitute and appoint EcoR1 Capital, LLC a Delaware limited liability company, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Securities Exchange Act of 1934, as amended, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present.

    Dated: February 14, 2024

    EcoR1 CAPITAL, LLC

     

     

    By: /s/ Oleg Nodelman

    Oleg Nodelman, Manager

     

     

     

     

     

    /s/ Oleg Nodelman
    Oleg Nodelman

    EcoR1 CAPITAL FUND QUALIFIED, L.P.

     

    By: EcoR1 Capital, LLC, General Partner

     

     

    By: /s/ Oleg Nodelman

    Oleg Nodelman, Manager

     

     

     

    Get the next $JANX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $JANX

    DatePrice TargetRatingAnalyst
    11/18/2025Peer Perform
    Wolfe Research
    9/17/2025$47.00Overweight
    Barclays
    9/10/2025$45.00Buy
    Stifel
    9/10/2025$100.00Buy
    Truist
    9/4/2025$72.00Buy
    Guggenheim
    8/19/2025$42.00Overweight
    Piper Sandler
    7/11/2025$65.00Outperform
    Raymond James
    12/3/2024$82.00 → $100.00Buy
    BTIG Research
    More analyst ratings

    $JANX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer

    Janux Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies based on its proprietary Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today announced that William Go, M.D., Ph.D., has been appointed Chief Medical Officer, effective January 26, 2026. Dr. Go succeeds Zachariah McIver, D.O., Ph.D., who will be leaving the Company to pursue other opportunities. Dr. Go brings more than 20 years of hematology and oncology experience, leading programs from early clinical development through pivotal trials, global regulatory approvals, and first-i

    1/26/26 7:00:00 AM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors

    Janux Therapeutics, Inc. (NASDAQ:JANX) ("Janux"), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb. Under the terms of the agreement, the companies will develop an undisclosed, novel, tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. "This collaboration marks a significant milestone for Janux, val

    1/22/26 7:00:00 AM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study

    Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies based on its proprietary Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today provided a program update on its ongoing Phase 1 study evaluating JANX008, its EGFR-targeted TRACTr, in multiple solid tumor indications. JANX008 is being evaluated in an ongoing Phase 1 study (NCT05783622) designed to assess safety, pharmacokinetics/pharmacodynamics, and evidence of clinical activity. The Phase 1a dose-escalation portion of the study has been completed, and the p

    12/23/25 4:05:00 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JANX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ra Capital Management, L.P. bought $25,342,965 worth of shares (824,041 units at $30.75) (SEC Form 4)

    4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

    3/7/25 6:05:32 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ra Capital Management, L.P. bought $53,700,000 worth of shares (1,200,000 units at $44.75) (SEC Form 4)

    4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

    10/22/24 4:20:04 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Reardon Tighe bought $4,988,643 worth of shares (849,854 units at $5.87) (SEC Form 4)

    4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

    11/15/23 4:48:17 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JANX
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Janux Therapeutics Inc.

    SCHEDULE 13G - Janux Therapeutics, Inc. (0001817713) (Subject)

    2/9/26 6:43:50 AM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Janux Therapeutics Inc.

    SCHEDULE 13G - Janux Therapeutics, Inc. (0001817713) (Subject)

    2/6/26 4:23:27 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Janux Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Janux Therapeutics, Inc. (0001817713) (Filer)

    1/22/26 4:30:59 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JANX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Go William was granted 44,000 shares (SEC Form 4)

    4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

    2/4/26 8:01:40 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Go William

    3 - Janux Therapeutics, Inc. (0001817713) (Issuer)

    2/4/26 8:00:24 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Campbell David Alan sold $110,829 worth of shares (8,072 units at $13.73) and was granted 96,600 shares, increasing direct ownership by 30% to 381,582 units (SEC Form 4)

    4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

    1/2/26 9:00:14 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JANX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Janux Therapeutics

    Wolfe Research initiated coverage of Janux Therapeutics with a rating of Peer Perform

    11/18/25 8:24:27 AM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Janux Therapeutics with a new price target

    Barclays initiated coverage of Janux Therapeutics with a rating of Overweight and set a new price target of $47.00

    9/17/25 8:02:27 AM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel initiated coverage on Janux Therapeutics with a new price target

    Stifel initiated coverage of Janux Therapeutics with a rating of Buy and set a new price target of $45.00

    9/10/25 4:00:02 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JANX
    Financials

    Live finance-specific insights

    View All

    Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs

    Multiple patients treated with PSMA-TRACTr JANX007 have achieved meaningful PSA drops coupled with manageable safety and CRS PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008 have been generally well tolerated at levels above the projected maximum tolerable dose of the parental T cell engagers JANX007 preliminary data showed encouraging safety results consistent with on-tumor activity with no dose-limiting toxicities PK exposure demonstrated TRACTr activation with lack of TCE accumulation No treatment-emergent ADA titers observed Janux to host virtual investor event today at 4:00 PM Eastern Time Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutica

    7/17/23 8:00:00 AM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JANX
    Leadership Updates

    Live Leadership Updates

    View All

    Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer

    Janux Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies based on its proprietary Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today announced that William Go, M.D., Ph.D., has been appointed Chief Medical Officer, effective January 26, 2026. Dr. Go succeeds Zachariah McIver, D.O., Ph.D., who will be leaving the Company to pursue other opportunities. Dr. Go brings more than 20 years of hematology and oncology experience, leading programs from early clinical development through pivotal trials, global regulatory approvals, and first-i

    1/26/26 7:00:00 AM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day

    PSMA-TRACIr designed to be combined with potentially best-in-treatment asset, JANX007, and provide CD28 co-stimulation to further differentiate depth and durability of patient responses. TROP2-TRACTr adds first-in-class and best-in-class opportunity targeting multiple solid tumors with preclinical data supporting differentiated safety and efficacy potential. CD19-ARM displayed rapid, deep and durable B-cell depletion in periphery and tissues with a prolonged memory B cell reset while maintaining a large safety window in non-human primates, advancing toward first-in-human trials anticipated to begin in the first half of 2026. Webcast to be held today at 1:30 PM PT. Janux Therape

    7/24/25 4:05:00 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Janux Therapeutics to Host Virtual R&D Day on July 24, 2025

    Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that it will host a virtual R&D Day at 1:30 PM PT on Thursday, July 24, 2025. The event will include a presentation from management highlighting product candidates identified from its preclinical pipeline to move into clinical trials. These previously undisclosed preclinical programs utilize Janux's expertise and platform technologies to potentially address significant unmet medical needs.

    7/17/25 4:30:00 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JANX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Janux Therapeutics Inc.

    SC 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)

    11/14/24 4:24:38 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Janux Therapeutics Inc.

    SC 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)

    11/14/24 4:17:06 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Janux Therapeutics Inc.

    SC 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)

    11/14/24 4:01:49 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care